Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

Yahoo FinanceNov 27 09:55 ET

Arcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term Fluctuations

TipRanksNov 25 02:36 ET

Bears Are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Zacks Nov 19 09:05 ET

Arcutis' ZORYVE (Roflumilast) Awarded Best Eczema Treatment by Glamour

Arcutis BiotherapeuticsNov 13 08:00 ET

Express News | Arcutis Biotherapeutics Inc : Guggenheim Raises Target Price to $29 From $27

ReutersNov 8 07:28 ET

Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsNov 7 07:31 ET · Ratings